Last reviewed · How we verify

VAS203 — Competitive Intelligence Brief

VAS203 (VAS203) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitric oxide synthase inhibitor. Area: Neurology.

phase 3 Nitric oxide synthase inhibitor Nitric oxide synthase (NOS) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

VAS203 (VAS203) — veriNOS operations GmbH. VAS203 is a nitric oxide synthase inhibitor that reduces nitric oxide production to protect against ischemic brain injury.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
VAS203 TARGET VAS203 veriNOS operations GmbH phase 3 Nitric oxide synthase inhibitor Nitric oxide synthase (NOS)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitric oxide synthase inhibitor class)

  1. veriNOS operations GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VAS203 — Competitive Intelligence Brief. https://druglandscape.com/ci/vas203. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: